{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:06:35Z","timestamp":1790208395842,"version":"4.1.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19-targeted immunotherapies have drastically improved outcomes for relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (ALL) patients. Such therapies, including blinatumomab and CD19 chimeric antigen receptor (CD19CAR) T cells, yield high remission rates and can bridge to more definitive consolidation therapy with curative intent. Both treatments are approved by the US Food and Drug Administration (FDA) for r\/r ALL (CD19CAR T-cell approval is restricted to patients \u226425 years old). Although availability of blinatumomab and CD19CAR T cells has extended options for the treatment of r\/r ALL, prioritizing the sequence of these agents on an individual-patient basis may be difficult for the treating physician. Considering each therapy\u2019s advantages, limitations, and challenges is necessary when choosing between them. Although patients may receive both blinatumomab and CD19CAR T cells sequentially in cases that fail to respond or subsequently relapse, a proportion of patients treated with CD19-targeted immunotherapy will lose expression of CD19 and will be excluded from receiving the alternative CD19-targeted therapy. Thus, weighing all considerations for each patient before selecting a CD19-targeted immunotherapy is crucial. Here, we discuss real-life scenarios of adults with r\/r ALL, in which we selected either blinatumomab or CD19CAR T-cell therapy, and the rationale behind each decision.<\/jats:p>","DOI":"10.1182\/blood.2019002132","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T15:53:22Z","timestamp":1578066802000},"page":"804-813","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy"],"prefix":"10.1182","volume":"135","author":[{"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"first","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2020031211595346300_B1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2020031211595346300_B2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2020031211595346300_B3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020031211595346300_B4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2020031211595346300_B5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"2020031211595346300_B6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"2020031211595346300_B7","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2020031211595346300_B8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol"},{"issue":"4","key":"2020031211595346300_B9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2020031211595346300_B10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3324\/haematol.2010.027862","article-title":"A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study","volume":"96","author":"Hunault-Berger","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2020031211595346300_B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JOP.18.00271","article-title":"Acute lymphoblastic leukemia in the older adult","volume":"15","author":"Aldoss","year":"2019","journal-title":"J Oncol Pract"},{"issue":"14","key":"2020031211595346300_B12","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"issue":"suppl 1","key":"2020031211595346300_B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2018-99-111992","article-title":"Results of SWOG 1318: a phase 2 trial of blinatumomab followed by pomp (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia [abstract]","volume":"132","author":"Advani","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020031211595346300_B14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2020031211595346300_B15","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2020031211595346300_B16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-019-0753-y","article-title":"Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: pathophysiology, prevention, and treatment","volume":"21","author":"Aldoss","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2020031211595346300_B17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020031211595346300_B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study [published correction appears in Lancet Oncol. 2015;16(4):e158]","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020031211595346300_B19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"issue":"36","key":"2020031211595346300_B20","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020031211595346300_B21","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2020031211595346300_B22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2020031211595346300_B23","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/blood.V122.21.3903.3903","article-title":"Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance) [abstract]","volume":"122","author":"Sanford","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020031211595346300_B24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bbmt.2015.10.016","article-title":"Implications and management of central nervous system involvement before allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9967","key":"2020031211595346300_B25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2020031211595346300_B26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","article-title":"A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia [published correction appears in J Hematol Oncol. 2019;12(1):117]","volume":"11","author":"Weng","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2020031211595346300_B27","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2020031211595346300_B28","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"He","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"2020031211595346300_B29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"issue":"36","key":"2020031211595346300_B30","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020031211595346300_B31","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020031211595346300_B32","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020031211595346300_B33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2020031211595346300_B34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [published correction appears in Blood. 2019;133(24):2625]","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2020031211595346300_B35","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020031211595346300_B36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2020031211595346300_B37","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2018-99-119883","article-title":"Adult patients with ALL treated with CD62L+ T naive\/memory-enriched T cells expressing a CD19-CAR mediate potent antitumor activity with a low toxicity profile [abstract]","volume":"132","author":"Khaled","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020031211595346300_B38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2020031211595346300_B39","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"544","key":"2020031211595346300_B40","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"issue":"15","key":"2020031211595346300_B41","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2020031211595346300_B42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation [abstract]","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2020031211595346300_B43","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia [abstract]","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020031211595346300_B44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/leu.2017.306","article-title":"Blinatumomab retreatment after relapse in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2018","journal-title":"Leukemia"},{"key":"2020031211595346300_B45","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"22","key":"2020031211595346300_B46","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2018-02-834911","article-title":"Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab","volume":"131","author":"Aldoss","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2020031211595346300_B47","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00277-017-3050-6","article-title":"Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy","volume":"96","author":"Balducci","year":"2017","journal-title":"Ann Hematol"},{"issue":"6","key":"2020031211595346300_B48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2020031211595346300_B49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bjh.15812","article-title":"Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure","volume":"186","author":"Lucero","year":"2019","journal-title":"Br J Haematol"},{"issue":"20","key":"2020031211595346300_B50","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2020031211595346300_B51","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","article-title":"Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy","volume":"130","author":"Nagel","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020031211595346300_B52","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"10","key":"2020031211595346300_B53","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2020031211595346300_B54","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","article-title":"Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia","volume":"102","author":"G\u00f6kbuget","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2020031211595346300_B55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ajh.24987","article-title":"Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2020031211595346300_B56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2020031211595346300_B57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"511","key":"2020031211595346300_B58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"18","key":"2020031211595346300_B59","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020031211595346300_B60","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2020031211595346300_B61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020031211595346300_B62","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma [published correction appears in Mol Ther. 2014;22(5):1063]","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2020031211595346300_B63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia [abstract]","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020031211595346300_B64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL) [abstract]","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020031211595346300_B65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000495558","article-title":"Relapsed Philadelphia chromosome-positive pre-B-ALL after CD19-directed CAR-T cell therapy successfully treated with combination of blinatumomab and ponatinib","volume":"141","author":"El Chaer","year":"2019","journal-title":"Acta Haematol"},{"key":"2020031211595346300_bib66","doi-asserted-by":"crossref","unstructured":"Zhao Y , AldossI, QuC, et al. Genomic determinants of response to blinatumomab in relapsed\/refractory (R\/R) B-cell precursor acute lymphoblastic leukemia in adults [abstract]. Blood. 2018;132(suppl 1). Abstract 1552.","DOI":"10.1182\/blood-2018-99-113604"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/11\/804\/1718625\/bloodbld2019002132c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/11\/804\/1718625\/bloodbld2019002132c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T14:41:14Z","timestamp":1722264074000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/11\/804\/430058\/How-I-treat-adults-with-advanced-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002132","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]}}}